[ad_1] Diving sheet: Janssen Biotech, of Johnson & Johnson, will end Friday a development and license agreement whose potential value will reach nearly $ 1 billion for Geron's imetelstat, an anticancer drug …
Read More »J & J abandons Geron's anti-cancer drug
